High Prevalence of Undocumented SARS-CoV-2 Infections in the Pediatric Population of the Tyrolean District of Schwaz.
SARS-CoV-2
anti-nucleocapsid antibody
anti-spike antibody
children
durable immune response
humoral response
neutralizing antibody
pediatric infection
seroprevalence
unreported infection
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
19 10 2022
19 10 2022
Historique:
received:
29
09
2022
revised:
13
10
2022
accepted:
14
10
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
29
10
2022
Statut:
epublish
Résumé
Complementing the adult seroprevalence data collected at the time of the rapid SARS-CoV-2 mass vaccination in the district of Schwaz in 2021, we set out to establish the seroprevalence of SARS-CoV-2 among the pediatric population of the district. A total of 369 children, mean age 9.9 (SD 3.4), participated in the study, answering a structured questionnaire on the history of SARS-CoV-2 infection, household contacts, symptoms and history of vaccination. We determined binding and neutralizing antibody levels using plasma samples provided. We estimated the overall prevalence of SARS-CoV-2 infection in the general pediatric population at the time of the study using the census data from Statistik Austria and daily reports of officially confirmed cases. Excluding study participants who reported a history of PCR-confirmed infection, the age-standardized seroprevalence of previously unknown SARS-CoV-2 infection among the general pediatric population of the district was 27% (95% CI: 26.1-27.8). Adding this to the officially documented cases, the true overall prevalence was 32.8% (95% CI: 31.9-33.6) in contrast to the officially documented 8.0% (95% CI: 7.5-8.5) by June 2021. This translated into a proportion of 75.7% (95% CI: 74.4-77.0) of cases being officially undocumented, suggesting a high extent of silent SARS-CoV-2 infections in the pediatric population and possibly silent transmission.
Identifiants
pubmed: 36298849
pii: v14102294
doi: 10.3390/v14102294
pmc: PMC9609860
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Antibodies, Neutralizing
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Nature. 2021 Apr;592(7854):438-443
pubmed: 33690265
Nat Immunol. 2022 Mar;23(3):351-353
pubmed: 35194206
Nat Biotechnol. 2022 Mar;40(3):319-324
pubmed: 34408314
Microbiol Spectr. 2021 Sep 3;9(1):e0029121
pubmed: 34406813
Front Public Health. 2022 Sep 09;10:989337
pubmed: 36159252
Vaccines (Basel). 2020 Dec 28;9(1):
pubmed: 33379160
Viruses. 2021 Jun 22;13(7):
pubmed: 34206453
Viruses. 2022 Jul 27;14(8):
pubmed: 36016265
Euro Surveill. 2020 Aug;25(31):
pubmed: 32762797
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
Nat Med. 2021 Mar;27(3):546-559
pubmed: 33654293
Methods Protoc. 2018 Jan 22;1(1):
pubmed: 31164554
Commun Med (Lond). 2021;1(1):4
pubmed: 34870284
Pediatr Infect Dis J. 2020 Dec;39(12):e388-e392
pubmed: 33031141
PLoS One. 2022 Jul 13;17(7):e0270694
pubmed: 35830378
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Clin Lab Med. 2022 Mar;42(1):85-96
pubmed: 35153050
Acta Paediatr. 2020 Jun;109(6):1088-1095
pubmed: 32202343
JAMA. 2020 Jun 16;323(23):2427-2429
pubmed: 32432657
Clin Infect Dis. 2020 Sep 12;71(6):1547-1551
pubmed: 32112072
Clin Infect Dis. 2020 Dec 3;71(9):2469-2479
pubmed: 32392337
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
Sci Rep. 2021 Feb 4;11(1):3044
pubmed: 33542262
Pediatrics. 2021 Sep;148(3):
pubmed: 34158312
CMAJ. 2021 Jan 4;193(1):E1-E9
pubmed: 33234533
EBioMedicine. 2021 Sep;71:103561
pubmed: 34455390
JAMA Pediatr. 2021 Oct 1;175(10):e212025
pubmed: 34115094
Pediatrics. 2020 Jun;145(6):
pubmed: 32179660
N Engl J Med. 2020 Apr 23;382(17):1663-1665
pubmed: 32187458
J Epidemiol Community Health. 2020 Nov 28;:
pubmed: 33249407
Nat Commun. 2022 Feb 1;13(1):612
pubmed: 35105889
Int J Epidemiol. 2022 Jan 6;50(6):1795-1803
pubmed: 34999848
JCI Insight. 2021 May 10;6(9):
pubmed: 33822777
Viruses. 2022 Mar 09;14(3):
pubmed: 35336975
Front Med (Lausanne). 2022 Jan 11;8:757459
pubmed: 35087843
BMC Infect Dis. 2022 Mar 29;22(1):311
pubmed: 35351016
JAMA Pediatr. 2021 Feb 1;175(2):143-156
pubmed: 32975552
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
N Engl J Med. 2021 Dec 30;385(27):2582-2585
pubmed: 34879193
Science. 2021 Jul 9;373(6551):
pubmed: 34035154
Front Public Health. 2021 Jul 05;9:645739
pubmed: 34291023
BMC Infect Dis. 2022 Aug 5;22(1):672
pubmed: 35931971
Pediatr Pulmonol. 2020 Aug;55(8):1892-1899
pubmed: 32492251
Infection. 2021 Oct;49(5):983-988
pubmed: 34032997
JCI Insight. 2021 Sep 8;6(17):
pubmed: 34228642
Pediatr Infect Dis J. 2020 May;39(5):355-368
pubmed: 32310621
J Clin Invest. 2021 Jan 4;131(1):
pubmed: 33180746
Nat Immunol. 2022 Feb;23(2):177-185
pubmed: 35105983
PLoS One. 2020 Dec 9;15(12):e0243597
pubmed: 33296437
Nat Commun. 2022 Jun 6;13(1):3128
pubmed: 35668073
Zhongguo Dang Dai Er Ke Za Zhi. 2021 Nov 15;23(11):1080-1090
pubmed: 34753538
Int J Environ Res Public Health. 2022 Apr 28;19(9):
pubmed: 35564779